LncRNA TONSL-AS1 regulates miR-490-3p/CDK1 to affect ovarian epithelial carcinoma cell proliferation
- PDF / 1,018,637 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 40 Downloads / 207 Views
RESEARCH
Open Access
LncRNA TONSL-AS1 regulates miR-490-3p/ CDK1 to affect ovarian epithelial carcinoma cell proliferation Yan Liu1†, Ling Li1†, Xiangyang Wang2, Ping Wang1 and Zhongxian Wang1*
Abstract Background: LncRNA TONSL-AS1 has been characterized as a critical player in gastric cancer. By analyze the TCGA dataset, we observed the upregulation of TONSL-AS1 in ovarian epithelial carcinoma (EOC). We therefore investigated the involvement of TONSL-AS1 in EOC. Methods: The differential expression of TONSL-AS1 in EOC was first explored by analyzing the TCGA dataset. The effects of overexpression of TONSL-AS1 and miR-490-3p on the expression of CDK1 mRNA and protein in OVCAR3 cells were evaluated by qPCR and western blot, respectively. CCK-8 assay was performed to investigate the effects of overexpression of TONSL-AS1, miR-490-3p and CDK1 on proliferation of OVCAR3 cells. Results: We observed that TONSL-AS1 was upregulated in EOC tumor tissues from EOC patients, and its high expression level was correlated with poor survival. Dual luciferase assay and RNA interaction prediction showed the direct interaction between TONSL-AS1 and miR-490-3p. However, overexpression of miR-490-3p did not affect the expression of TONSLAS1. Instead, overexpression of TONSL-AS1 resulted in the upregulation of CDK1, a target of miR-490-3p, in EOC cells. Overexpression of TONSL-AS1 and CDK1 resulted in increased proliferation rate of EOC cells. Overexpression of miR-4903p played an opposite role and reduced the effects of overexpression of TONSL -AS1 and CDK1. Conclusions: Therefore, TONSL-AS1 may regulate miR-490-3p/CDK1 to affect EOC cell proliferation. Keywords: Ovarian epithelial carcinoma, TONSL-AS1, Survival, miR-490-3p, CDK1
Background Ovarian carcinoma is the 7th most commonly diagnosed malignancy among females worldwide and the 10th most common cancer in China [1]. In 2018, ovarian cancer caused 184,799 deaths, accounting for 1.9% of all cancer deaths. In the same year, a total of 295,414 new cases of ovarian cancer were diagnosed [2]. More than 85% of ovarian carcinomas are ovarian epithelial carcinoma (EOC) [3]. With the development of cancer therapies, such as local and systemic chemotherapy, radiation * Correspondence: [email protected] † Yan Liu and Ling Li contributed equally to this work. 1 Department of Obstetrics and Gynecology, Wuhan No.1 Hospital, No. 215 Zhongshan Avenue, Wuhan City, Hubei Province 430022, PR China Full list of author information is available at the end of the article
therapies and surgical resection of primary tumors, the overall survival of EOC has been improved significantly during the past several decades [4, 5]. However, prognosis of EOC patients diagnosed at advanced stages is still poor [6]. Therefore, novel therapies are of great importance. It has been well established that genetic factors are critical players in the pathogenesis of EOC [7]. Identification of critical players in EOC may provide new targets for the development of targeted therapies [8]. Cyclin-dependent kinase 1 (
Data Loading...
